Wall Street analysts predict that Magenta Therapeutics Inc (NASDAQ:MGTA) will announce earnings per share (EPS) of ($0.55) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Magenta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.55) and the highest estimate coming in at ($0.54). The business is scheduled to announce its next quarterly earnings report on Thursday, February 28th.
On average, analysts expect that Magenta Therapeutics will report full year earnings of ($3.19) per share for the current year, with EPS estimates ranging from ($3.23) to ($3.15). For the next financial year, analysts expect that the firm will post earnings of ($2.05) per share, with EPS estimates ranging from ($2.67) to ($1.12). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Magenta Therapeutics.
A number of equities analysts recently issued reports on MGTA shares. Zacks Investment Research upgraded shares of Magenta Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, December 13th. ValuEngine lowered shares of Magenta Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.33.
MGTA stock traded up $1.91 during trading on Tuesday, reaching $15.02. 154,207 shares of the company were exchanged, compared to its average volume of 62,559. Magenta Therapeutics has a twelve month low of $5.31 and a twelve month high of $16.33.
Magenta Therapeutics Company Profile
Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.
Recommended Story: What is a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.